The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.
Non-interventional study: subjects to be selected according to the usual clinical practice of their physician
Study Type
OBSERVATIONAL
Enrollment
288
Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Pfizer Investigational Site
Vienna, State of Vienna, Austria
Mean Number of Bleeding Episodes Per Patient Year
Participants with hemophilia A suffer from a hereditary lack of blood clotting factor VIII. As a consequence, the ability of the blood to coagulate is reduced and bleedings at any site or organ of the body may occur after minor injury or even spontaneously. Predominantly, joints, muscles, and internal organs are affected by bleeding complications. Participants reported the occurrence of each bleeding episode while on study. The bleeding rate for each participant was calculated by number of reported episodes per years on study.
Time frame: Baseline up to a mean duration of 54 months
Mean Number of Bleeding-related Exposure Days Per Patient Year
Exposure days are the number of days of treatment with ReFacto.
Time frame: Baseline up to a mean duration of 54 months
Mean Number of Exposure Days Per Patient Year
Exposure days are the number of days of treatment with ReFacto.
Time frame: Baseline up to a mean duration of 54 months
Number of Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
AEs are any undesired side effect which occurred in a participant undergoing study treatment independent of whether a correlation with study treatment was suspected or not. SAEs are undesired events which were lethal or life-threatening, made hospitalization or extension of hospital stay necessary, lead to permanent damage with handicap (inability to work), as well as congenital anomalies, malignant disease, or overdosing. Also presence of inhibitors, thrombotic events, erythrocyte agglutination, allergic reactions, less than therapeutic effect, and inhibitor development were considered SAEs.
Time frame: Baseline up to a mean duration of 54 months
Number of Participants With de Novo Inhibitor Formation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Berlin, Germany, Germany
Pfizer Investigational Site
Wiesbaden, Germany, Germany
Pfizer Investigational Site
Frankfurt am Main, Hesse, Germany
Pfizer Investigational Site
Giessen, Hesse, Germany
Pfizer Investigational Site
Hanover, Lower Saxony, Germany
Pfizer Investigational Site
Rostock, Mecklenburg-Vorpommern, Germany
Pfizer Investigational Site
Bonn, North Rhine-Westphalia, Germany
Pfizer Investigational Site
Halle, Saxony-Anhalt, Germany
Pfizer Investigational Site
Stadtroda, Thuringia, Germany
...and 16 more locations
The applied criteria of clinical relevance for de novo inhibitor formation was defined as normal Factor VIII dosage was ineffective to control a bleeding, control of bleeding episodes required increasing Factor VIII dosage, change of concentrate type (administration of activated Prothrombin-Complex Concentrate \[aPCC\] or recombinant Factor VII \[rFVII \]) was needed to stop a bleeding, or change of therapy strategy (intensive prophylaxis or Immune Tolerance Induction \[ITI\]) was required.
Time frame: Baseline up to a mean duration of 54 months
Mean Annual ReFacto Consumption Per Patient Year
ReFacto administered as International Units (IU) according to the physician's decision following the drug's summary of product characteristics (SPC) and according to usual care principles.
Time frame: Baseline up to a mean duration of 54 months
Number of Participants for Physicians' Assessment of Satisfaction With Treatment Success
Subjective assessment by the physician to evaluate treatment success (i.e., control of bleeding, Factor VIII consumption, treatment efficacy and tolerance, handling of preparation, and days missing from work or school). Physician rated assessment could be categorized as Very satisfied, Satisfied, Unsatisfied, or Very unsatisfied; no criteria was pre-specified for the assessment categories in this observational study.
Time frame: Baseline up to a mean duration of 54 months
Number of Participants for Physicians' Assessment of Efficacy
Subjective assessment by the physician to evaluate control of bleeding. Physician rated assessment could be categorized as Very good, Good, Moderate, or Poor; no criteria was pre-specified for the assessment categories in this observational study.
Time frame: Baseline up to a mean duration of 54 months
Number of Participants for Patients' Assessment of Efficacy
Subjective assessment by the participant to evaluate control of bleeding. Patient rated assessment could be categorized as Very good, Good, Moderate, Poor, or No specification; no criteria was pre-specified for the assessment categories in this observational study.
Time frame: Baseline up to a mean duration of 54 months
Number of Participants for Physicians' Assessment of Tolerance
Subjective assessment by the physician to evaluate the participants' tolerance of treatment with ReFacto (i.e., dose, administration method, or adverse effects). Physician rated assessment could be categorized as Very good, Good, Moderate, or Poor; no criteria was pre-specified for the assessment categories in this observational study.
Time frame: Baseline up to a mean duration of 54 months
Number of Participants for Patients' Assessment of Tolerance
Subjective assessment by the participant to evaluate tolerance of treatment with ReFacto (i.e., dose, administration method, or adverse effects). Patient rated assessment could be categorized as Very good, Good, Moderate, Poor, or No specification; no criteria was pre-specified for the assessment categories in this observational study.
Time frame: Baseline up to a mean duration of 54 months
Number of Participants for Physicians' Assessment of Handling of ReFacto
Subjective assessment by the physician to evaluate the participants' handling (preparation and administration) of ReFacto. Physician rated assessment could be categorized as Very good, Good, Moderate, or Poor; no criteria was pre-specified for the assessment categories in this observational study.
Time frame: Baseline up to a mean duration of 54 months
Number of Participants for Patients' Assessment of Handling of ReFacto
Subjective assessment by the participant on handling (preparation and administration) of ReFacto. Patient rated assessment could be categorized as Very good, Good, Moderate, Poor, or No specification; no criteria was pre-specified for the assessment categories in this observational study.
Time frame: Baseline up to a mean duration of 54 months
Number of Participants for Days of Sick Leave Per Month
Days of sick leave (missing work or school) per month categorized as No days of absence, Number of days of absence, Long-term inability to work or study, Not employed or at school, or No specification.
Time frame: Baseline up to a mean duration of 54 months